MAIA Company Profile and Key Details

MAIA Biotechnology, Inc. generated EPS of -$0.74 over the past year. Five-year average earnings growth is -11.4%. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.13. Next year's EPS is expected at -$6.02. MAIA Biotechnology, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -22.22%. The prior quarter beat by -22.22%. Over the last six quarters, Apple has recorded several small beats. These include -11.11% in May 09, 2025.

MAIA has shown sold momentum, gaining 40.13% over the past week and 71.88% over the past quarter, though year-to-date performance is up 43.79%. Short-term trend indicators are bearishly aligned (SMA20 4.91%, SMA50 16.87%, SMA200 33.91%). The stock’s 14-day RSI is 53.91 (neutral), while the ATR of 0.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.66% below its high and over 150.57% above its low. Average 10-day trading volume of 609.27 thousand shares is below the 3-month average of 699.87 thousand, indicating normal recent market interest.

MAIA Biotechnology, Inc. has 32.99 million shares outstanding. The public float is 28.34 million shares, elevated short interest at 2.20% of float. This equals 626.63 thousand shares. The short ratio is 1.43 days. Institutional investors hold 8.81% of the float. Insiders own 21.43%. Smith Stan holds 1.52 million shares, Vitoc Vlad has 976.12 thousand shares and Luput Cristian has 437.63 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

MAIA Biotechnology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.43. This means the shares are trading above this model’s fair value.

MAIA Biotechnology, Inc. (AMEX:MAIA) closed at $1.46 USD, losing -$0.01 (-0.68%) from the previous close of $1.47. The stock is currently mid-range between its 52-week high and low $0.87 and $3.19. With a market capitalization of about $88.77 million, MAIA Biotechnology, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.23). Key stats such as the average daily volume over the past year has been around 743.54 thousand shares, volume is running light vs its 52-week average. Headquartered in Chicago, IL, MAIA Biotechnology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Vlad Vitoc, the company employs approximately 13 people and listed since July 28, 2022. MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer.

MAIA Biotechnology, Inc. trades at a P/E ratio of -2.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.68 suggesting the stock is closer to book value. The P/FCF stands at -4.42, also above market averages.

MAIA Biotechnology, Inc. (AMEX:MAIA) shares are up 43.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MAIA Biotechnology, Inc. trading at a premium to the broader market with a P/E of -2.12. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.00, suggesting 858.9% upside. Our AI forecast model points to short-term strength (4.79% over two weeks), a medium-term fall (-63.01% over three months), and a longer-term gain (243.15% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MAIA Biotechnology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.79%, with price expected at $1.53 by July 22, 2026, within a range of $1.46 to $1.59 3-Month Outlook: Projected fall of -63.01%, reaching $0.54 by October 06, 2026, with a range of $0.43 to $0.61. 1-Year Outlook: Projected gain of 243.15%, with price at $5.01 by July 08, 2027, within a range of $0.00 to $6.57.